OC
ORTX

Oppenheimer & Co’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Oppenheimer & Co’s Portfolio ORTX Stock Details ORTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,150
Closed -$4.27K – 1465
2022
Q4 		$4.27K Sell
1,150
-20
-2% -$88 ﹤0.01% 1347
2022
Q3 		$6K Sell
1,170
-240
-17% -$1.34K ﹤0.01% 1358
2022
Q2 		$8K Buy
1,410
+250
+22% +$1.41K ﹤0.01% 1400
2022
Q1 		$8K Buy
+1,160
New +$11.4K ﹤0.01% 1461

Other funds holding ORTX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
KI
Kapitalo Investimentos Sao Paulo, Brazil $531M AUM 25.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Oppenheimer & Co's ORTX Position: Q1 2023 in Review

Oppenheimer & Co sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2023, closing a stake of 1,150 shares — an estimated $4.27K sold.

Oppenheimer & Co first reported a position in ORTX in Q1 2022 and held it in 4 quarters. The position peaked at $8K in Q2 2022. 35 funds tracked by Wall St. Rank hold ORTX as of Q1 2023.

  • Oppenheimer & Co reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2023 after selling out during the quarter.
  • Oppenheimer & Co sold 1,150 Orchard Therapeutics plc American Depositary Shares shares in Q1 2023, an estimated $4.27K.
  • Oppenheimer & Co first reported a position in Orchard Therapeutics plc American Depositary Shares in Q1 2022 and held it in 4 quarters.
  • Oppenheimer & Co's Orchard Therapeutics plc American Depositary Shares position peaked at $8K in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2023.

Based on Oppenheimer & Co's 13F filing for Q1 2023, filed 10 May 2023.